The structure of the drug transport that uses Nano has become a device to change in cancer. But a successful combination in clinical practice, how to improve in the test tubes and in the standard body efforts for identifying clinical experiments and designs related to important achievements for translation success, including biological compatibility, profile, launching drugs and target setting techniques. The comprehensive inspection of landscapes, rules, and regulations of important agencies, including FDA and EMA, the work frame of the class and indicators for the approval of nano doctors also summarize the challenges of dealing with risk only particles. A case study of nano particles that have been accepted to present valuable in-depth information and important obstacles and events of their scientific travel, focusing on classes for the development of fate, ethics and society, including personal safety that is affected, transparent in clinical experiments and equally accessible. The end of bankruptcy emphasizes the procurement of fate, progress in science, supervision, mutual efforts between stakeholders and innovation to improve the translation method. This comprehensive analysis provides a guide for researchers, physicians, and regulators in navigating the complex area of ​​nanoparticle-based cancer care.